TAISF yields 1.25% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, TAISF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TAISF + JNJ for your $10,000?
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
Full TAISF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.